MYCO 004
Alternative Names: MYCO-004Latest Information Update: 28 Jul 2025
At a glance
- Originator Mydecine Innovations Group
- Class Neuropsychotherapeutics; Tryptamines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Smoking withdrawal; Substance-related disorders
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for research development in Smoking-withdrawal in USA (Transdermal, Patch)
- 28 May 2025 No recent reports of development identified for research development in Substance-related disorders in USA (Transdermal, Patch)
- 06 Dec 2021 Mydecine Innovations Group files for patent protection for psilocin and psilocybin’s active metabolite including MYCO 004